List of Steglatro drug patents

Steglatro is owned by Merck Sharp Dohme.

Steglatro contains Ertugliflozin.

Steglatro has a total of 1 drug patent out of which 0 drug patents have expired.

Steglatro was authorised for market use on 19 December, 2017.

Steglatro is available in tablet;oral dosage forms.

Steglatro can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

The generics of Steglatro are possible to be released after 13 July, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080580 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M (M) Sep 17, 2024

Drugs and Companies using ERTUGLIFLOZIN ingredient

Market Authorisation Date: 19 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

How can I launch a generic of STEGLATRO before it's patent expiration?
More Information on Dosage

STEGLATRO family patents

3

United States

2

China

2

Korea, Republic of

2

Hong Kong

2

Israel

1

Portugal

1

El Salvador

1

Malaysia

1

Uruguay

1

Panama

1

Spain

1

Brazil

1

Croatia

1

Costa Rica

1

Colombia

1

IB

1

New Zealand

1

AP

1

Dominican Republic

1

Norway

1

Argentina

1

Mexico

1

Austria

1

Morocco

1

Peru

1

Taiwan, Province of China

1

Honduras

1

Tunisia

1

EA

1

Nicaragua

1

South Africa

1

Lithuania

1

Canada

1

Japan

1

Cyprus

1

Slovenia

1

Hungary

1

ME

1

Ukraine

1

Cuba

1

Poland

1

Georgia

1

Chile

1

Australia

1

RS

1

Ecuador

1

Denmark

1

Netherlands

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in